These models collectively explain the efficacy of PARP inhibitors in targeting cancer cells with specific genetic deficiencies, particularly those involving BRCA1/2 mutations, thereby providing a rationale for their use in targeted cancer therapies. This evidence concerns the gene BRCA1 and cancer.